Anyways that's at the least two decades away if even that, for what can at best be defined as recreational gene therapy.
Depends on the side effects, depends if you can safely and reliably reverse the decision.
Would I personally be patient zero? No, not likely. Will someone be patient zero? Yeah, of course, there's always people willing to be on a new frontier.
Can you safely and reliably reverse a find/replace on a program's source? Generally, unless you have a backup, the answer is no. There's also a lack of any kind of guarantee that the resulting program will compile, or if it does, that it will run without any more bugs than it had before.
CRISPR is just about the same way. We need to do research in ethical and humane ways, ways that balance the possible gains with the possible losses. We've already had an incident where human DNA was edited, and not particularly ethically or responsibly. I'd really wish that people not bring sci-fi futurist fantasy thinking to this particular table.
Bad analogy as source code is one of the things that is super easy to reliably reverse anything as it is always in version control.
Would you CRISPR yourself to not get Alzheimers or Dementia when you get old?
Making myself smarter or healthier or stronger would be a no-brainer.
>Whether acute klotho elevation represents a strategy that can rapidly enhance cognition, motor functions, and/or induce brain resilience is a gap in our knowledge of its therapeutic potential. Here we show that αKL-F, a fragment of the α-klotho protein similar to its secreted form, can acutely improve cognitive and motor functions following peripheral administration. It does so despite apparent impermeability to the blood-brain barrier in young, aging, and hSYN transgenic mice. Further investigation of αKL-F-mediated molecular mechanisms revealed activation of glutamatergic signaling and enhancement of synaptic plasticity.
https://www.cell.com/cell-reports/fulltext/S2211-1247(17)309...
So the research around klotho may produce something which doesn't actually need to cross the BBB as a retail drug, but on a simultaneous front, we have gene manipulation via CRISPR that would also increase klotho production.